Efficacy of Ga-68-PSMA PET/CT-derived whole-body volumetric parameters in predicting response to second-generation androgen receptor axis-targeted therapy, and the prognosis in metastatic hormone-refractory prostate cancer patients
Yükleniyor...
Tarih
2021
Yazarlar
Oruç, Zeynep
Güzel, Yunus
Ebinç, Senar
Kömek, Halil
Küçüköner, Mehmet
Kaplan, Muhammet Ali
Oruç, İdris
Urakçı, Zuhat
Işıkdoğan, Abdurrahman
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Lippincott William & Wilkins
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Introduction The present study investigates the role of Ga-68-PSMA PET/CT-derived whole-body metabolic and volumetric parameters in the prediction of treatment response and prognosis among metastatic hormone-refractory prostate cancer patients undergoing second-generation androgen receptor axis-targeted therapy (abiraterone or enzalutamide). Materials and methods This retrospective study included 44 metastatic hormone-refractory prostate cancer patients undergoing Ga-68-PSMA PET/CT, including 29 enzalutamide-treated and 15 abiraterone-treated patients. Results Of the 44 patients included in the study, 29 received enzalutamide and 15 received abiraterone. During treatment, the changes in PET parameters were correlated with the PSA (biochemical) response. More specifically, a positive correlation was noted between PSA response and percent change in TLP (Delta TLP) response, and there was concordance between the results (r = 0.652, k = 0.42, P < 0.001). Baseline PSA (P =0.05), high MTVw (P = 0.005), the increase in Delta PSA (P = 0.036), Delta TLP (P = 0.039) and percent change in MTV (Delta MTV) (P = 0.049) values were identified as factors associated with mortality risk.Multivariate analysis showed that PSA1 [odds ratio (OR): 1.005, 95% confidence interval (CI) 1.002-1.008, P = 0.004], Delta PSA (OR: 14.7, 95% CI 1.50-143.7, P = 0.02) and MTVw1 (OR: 11.4, 95% CI 1.11-116, 6, P = 0.04) were independent prognostic factors associated with mortality risk. Conclusion A statistically significant concordance and correlation was noted between Ga-68-PSMA PET/CT-derived whole-body metabolic parameters (Delta TLP and Delta MTV) and Delta PSA. In addition, the baseline PSA, Delta PSA, Delta TLP, Delta MTV and TMTV were identified as predictive factors for mortality risk.
Açıklama
WOS:000717544600006
PMID: 34366407
PMID: 34366407
Anahtar Kelimeler
68Ga-PSMA PET/CT, Abiraterone, Enzalutamide, Prostate cancer, Quantitative tumor parameters
Kaynak
Nuclear Medicine Communications
WoS Q Değeri
Q4
Scopus Q Değeri
Q3
Cilt
42
Sayı
12
Künye
Oruç, Z., Güzel, Y., Ebinç, S., Kömek, H., Küçükoner, M., Kaplan, M.A. ve diğerleri. (2021). Efficacy of Ga-68-PSMA PET/CT-derived whole-body volumetric parameters in predicting response to second-generation androgen receptor axis-targeted therapy, and the prognosis in metastatic hormone-refractory prostate cancer patients. Nuclear Medicine Communications, 42(12), 1336-1346.
